Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

Autor: Eve Versage, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin, Matthew Hohenboken

Publikováno v: Vaccines, Vol 9, Iss 12, p 1468 (2021)

Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammal

Externí odkaz: https://doaj.org/article/9b10f15d75cc496abe308d895d57d9c0

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Autor: Christopher P. Evans, Ad Theeuwes, Bertrand Tombal, Fred Saad, Peter F.A. Mulders, Steve van Os, Teuvo L.J. Tammela, Go Kimura, Celestia S. Higano, Anders Bjartell, Kurt Miller, Michael Borre, Tomasz M. Beer, Suha Sari, Peter Iversen, Cora N. Sternberg, Andrew J. Armstrong, Dana E. Rathkopf, Choung Soo Kim, Yohann Loriot, Teresa Parli

Publikováno v: European urology, vol 71, iss 2
Beer, T M, Armstrong, A J, Rathkopf, D, Loriot, Y, Sternberg, C N, Higano, C S, Iversen, P, Evans, C P, Kim, C-S, Kimura, G, Miller, K, Saad, F, Bjartell, A S, Borre, M, Mulders, P, Tammela, T L, Parli, T, Sari, S, van Os, S, Theeuwes, A & Tombal, B 2017, ' Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study ', European Urology, vol. 71, no. 2, pp. 151-154 . https://doi.org/10.1016/j.eururo.2016.07.032
European Urology, 71, 2, pp. 151-154
European Urology, 71, 151-154

Contains fulltext : 173185.pdf (Publisher’s version ) (Closed access) Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naive metastatic castration-resistant pros

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5bfdd1d1b5d5d053f7ab96f40984a6
https://doi.org/10.1016/j.eururo.2016.07.032

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Autor: Young Deuk Choi, Ad Theeuwes, Sangeun Lee, Go Kimura, Choung Soo Kim, Edmund Chiong, Hyun Moo Lee, Weber Kam On Lau, Tomasz M. Beer, Bertrand Tombal, Takeshi Ueda, Junji Yonese, Takashi Fukagai, Sarang Abhyankar

Publikováno v: Medicine (Baltimore), Vol. 96, no. 27, p. e7223 [1-9] (2017)
Medicine

Supplemental Digital Content is available in the text
Background: Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-contro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b867e566a5202ffa7e6da2706531d2b9
https://hdl.handle.net/2078.1/186353

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

Autor: Olivier Rascol, Guus J. M. van Scharrenburg, Anthony E. Lang, Serge V. van de Witte, Ad Theeuwes, Robert A. Hauser, Cristina Sampaio, Juliana Bronzova

Publikováno v: Movement Disorders. 25:738-746

This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardopr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b13ada9295c80bb12de317ea02e15fd
https://doi.org/10.1002/mds.22948

Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study

Autor: Heike, Benecke, Herminio, Pérez-Garrigues, Dinsuhaimi, Bin Sidek, Ingrida, Uloziene, Kuessner, D, Eric, Sondag, Ad, Theeuwes, Algarra J, Marco

Publikováno v: The international tinnitus journal. 16(1)

This was a 3-month multicentre, open-label post-marketing surveillance study of betahistine (24 mg b.i.d. or 16 mg t.i.d.) in patients with vertigo of peripheral vestibular origin. Study endpoints comprised on-treatment changes in the Dizziness Handi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f05539b070effca4987cb2ea4aad0357
https://pubmed.ncbi.nlm.nih.gov/21609908